14-May-2019: The global sustained release excipients market
size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during the
forecast period, according to a new report by Grand View Research, Inc.
Increasing focus on novel drug delivery R&D and rising adoption of extended
release formulations for treatment of chronic diseases are major factors
driving the market.
Use of sustained release drug
formulations provides patients relief from these symptoms and helps maintain
desired therapeutic drug levels in the body. In comparison to conventional
drugs, sustained drug release technologies provide a wide range of benefits.
Reduced dosage frequency, improved patient compliance, maintenance of constant
level of drug in blood plasma, lower instances of toxicity due to overdose, and
higher cost-effectiveness in the long run are some of the major advantages of
using this technology.
Global rise in incidence of
chronic and infectious diseases has also resulted in antibiotic resistance,
which negatively affects the market for conventional dosage forms. Thus,
alternative methods to manage and treat these diseases are being implemented.
Use of sustained release formulations has been widely accepted among physicians
in order to combat antibiotic resistance. Since these formulations create
desired therapeutic drug levels in blood plasma and reduce dosage frequency,
they are the preferred choice of formulation among physicians, which increases
their demand.
In depth research report on Sustained Release Excipients Market
Further
key findings from the report suggest:
· Polymers
formed the largest revenue grossing segment by product type in 2017 and is
anticipated to grow at a lucrative rate during the forecast period. This is due
to its high adoption in sustained release formulations as they provide greater
strength and improved shelf-life
· In
terms of route of administration, the oral segment held the dominant share in
2017 and is projected to witness steady growth to retain its lead throughout
the forecast period
· Transdermal
technology is expected to exhibit the highest CAGR during the forecast period
owing to its escalating usage. It minimizes various limitations associated with
oral and parenteral route of administrations
· North
America dominated the overall market in 2017 due to well-developed research
infrastructure and presence of leading pharmaceutical and biopharmaceutical
companies
· Asia
Pacific is spearheading revenue growth, with Japan, China, and India at the
forefront
· Some of
the key companies in the market are Coating Place, Inc.; Depomed, Inc.; Corium
International, Inc.; Capsugel; Aradigm Corporation; Orbis Biosciences, Inc.;
and Alkermes plc.
Grand View Research has
segmented the global sustained release excipients market on the basis of
product, route of administration, technology, and region:
Sustained
Release Excipients Product Outlook (Revenue, USD Million, 2015 - 2026)
· Gelatin
· Polymers
· Minerals
· Sugars
· Alcohol
· Chitosan
Sustained
Release Excipients Route of Administration Outlook (Revenue, USD Million, 2015
- 2026)
· Oral
· Intramuscular
· Subcutaneous
· Transdermal
· Vaginal
· Ophthalmic
· Intravenous
· Others
Sustained
Release Excipients Technology Outlook (Revenue, USD Million, 2015 - 2026)
· Targeted
Delivery
· Micro
Encapsulation
· Wurster
Technique
· Transdermal
· Implants
· Coacervation
· Others
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment